The Competition Commission of India is expected to require certain concessions from pharmaceutical giants Ranbaxy Laboratories and Sun Pharmaceutical before they are given clearance to merge, say reports.
According to an unnamed source, the CCI will likely recommend “structural remedies” to ensure competition is not harmed from the transaction. Those remedies, reports say, may include selling assets, though neither company commented on the reports.
Sun first announced last April that it has reached an agreement with Japan-based Daiichi Sankyo to acquire Ranbaxy for about $4 billion. The companies expect to close the deal by the end of the year.
The CCI is reportedly set to send a letter to the companies suggesting its concessions; the unnamed source said the watchdog will also likely establish “a monitoring agency to ensure adherence consequent to the order.”
Full content: Business Standard
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI